LAUSR

Background: The Indian Bronchiectasis registry is an extension of EMBARC Registry started in 2015 by Respiratory Research Network of India to get better insights into its demographics, aetiology, co-morbidities and treatment practices in India. Methods: 18 investigator sites of the RRNI across India completed a web-based registry case report comprising of demographic details, risk factors, aetiology, HRCT, spirometry and treatment. Results: 964 patients of non-CF bronchiectasis were enrolled in this registry, of which 581(60.27%) were males. The mean age of participants was 52.59±15.32 years. The commonest pattern on HRCT was Cystic Bronchiectasis (66%) followed by cylindrical(41.2%) and varicose(12.7%) types. Cardiovascular disease was the commonest comorbidity(17%) followed by diabetes(15.8% ). The commonest aetiology for Bronchiectasis was Post TB(32.16%), followed by Idiopathic(23.5%) and post Infective(22.5%). ABPA related Bronchiectasis was seen in 11.4% cases. The quality of life (MRC Dyspnoea scale) was worst when the aetiology was TB(MRC≥3= 65%). Majority were never-smokers(70.6%) with only 5.7% being current smokers. The commonest inhaled prescriptions were ICS/LABA combination(71.75%) followed by Tiotropium(22.54%) and LABA(22.11%). Only 241 patients were prescribed antibiotics, of which 55.19% patients received low-dose macrolides(Azithromycin-31.1%), while cyclical antibiotic therapy was given to 29.4% patients. The commonest non-respiratory prescription was PPI(33%) followed by a statin(8.6%). 41.90% patients received pneumococcal vaccine. 44.09% received Influenza vaccine in last 1 year. Conclusions: EMBARC India Registry offers novel insights into non- CF Bronchiectasis in India.